Wet Age-Related Macular Degeneration (AMD) Drugs Market - Global Opportunity Analysis and Industry Forecast, 2020-2027
|
LI_184844
|
Pages: NA
|
Mar 2020 |
492 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING/MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4 WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. LUCENTIS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast (Value & Volume)
4.2.4. Market size and forecast by region
4.2.5. Market size and forecast by country
4.3. AVASTIN
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast (Value & Volume)
4.3.4. Market size and forecast by region
4.3.5. Market size and forecast by country
4.4. EYLEA
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast (Value & Volume)
4.4.4. Market size and forecast by region
4.4.5. Market size and forecast by country
4.5. OTHER DRUGS
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast (Value & Volume)
4.5.4. Market size and forecast by region
4.5.5. Market size and forecast by country
CHAPTER 5 WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. HOSPITALS
5.2.1. Market size and forecast by region
5.2.2. Market size and forecast by country
5.3. OPHTHALMIC CLINICS
5.3.1. Market size and forecast by region
5.3.2. Market size and forecast by country
5.4. RESEARCH INSTITUTES
5.4.1. Market size and forecast by region
5.4.2. Market size and forecast by country
5.5. CONTRACT RESEARCH ORGANIZATIONS
5.5.1. Market size and forecast by region
5.5.2. Market size and forecast by country
CHAPTER 6 WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. North America Wet Age-Related Macular Degeneration (AMD) Drugs Market by Country
6.2.3.1. U.S.
6.2.3.1.1. U.S. Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.2.3.1.2. U.S. Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.2.3.2. Canada
6.2.3.2.1. Canada Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.2.3.2.2. Canada Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.2.3.3. Mexico
6.2.3.3.1. Mexico Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.2.3.3.2. Mexico Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.2.4. North America Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.2.5. North America Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Europe Wet Age-Related Macular Degeneration (AMD) Drugs Market by Country
6.3.3.1. Germany
6.3.3.1.1. Germany Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.3.3.1.2. Germany Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.3.3.2. France
6.3.3.2.1. France Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.3.3.2.2. France Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.3.3.3. UK
6.3.3.3.1. UK Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.3.3.3.2. UK Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.3.3.4. Italy
6.3.3.4.1. Italy Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.3.3.4.2. Italy Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.3.3.5. Spain
6.3.3.5.1. Spain Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.3.3.5.2. Spain Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.3.3.6. Rest of Europe
6.3.3.6.1. Rest of Europe Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.3.3.6.2. Rest of Europe Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.3.4. Europe Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.3.5. Europe Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Asia-Pacific Wet Age-Related Macular Degeneration (AMD) Drugs Market by Country
6.4.3.1. Japan
6.4.3.1.1. Japan Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.4.3.1.2. Japan Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.4.3.2. China
6.4.3.2.1. China Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.4.3.2.2. China Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.4.3.3. Australia
6.4.3.3.1. Australia Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.4.3.3.2. Australia Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.4.3.4. India
6.4.3.4.1. India Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.4.3.4.2. India Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.4.3.5. South Korea
6.4.3.5.1. South Korea Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.4.3.5.2. South Korea Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.4.3.6. Rest of Asia-Pacific
6.4.3.6.1. Rest of Asia-Pacific Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.4.3.6.2. Rest of Asia-Pacific Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.4.4. Asia-Pacific Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.4.5. Asia-Pacific Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. LAMEA Wet Age-Related Macular Degeneration (AMD) Drugs Market by Country
6.5.3.1. Brazil
6.5.3.1.1. Brazil Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.5.3.1.2. Brazil Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.5.3.2. Saudi Arabia
6.5.3.2.1. Saudi Arabia Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.5.3.2.2. Saudi Arabia Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.5.3.3. South Africa
6.5.3.3.1. South Africa Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.5.3.3.2. South Africa Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.5.3.4. Rest of LAMEA
6.5.3.4.1. Rest of LAMEA Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.5.3.4.2. Rest of LAMEA Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
6.5.4. LAMEA Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type
6.5.5. LAMEA Wet Age-Related Macular Degeneration (AMD) Drugs Market by End User
CHAPTER 7 COMPANY PROFILES
7.1. F. HOFFMANN-LA ROCHE LTD
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. NOVARTIS INTERNATIONAL AG
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. GENENTECH, INC.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. REGENERON PHARMACEUTICALS, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. BAYER AG
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. VALEANT PHARMACEUTICALS INTERNATIONAL INC.
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. OPHTHOTECH CORPORATION
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. OHR PHARMACEUTICAL INC.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. MOLECULAR PARTNERS AG
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. ACUCELA INC.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
Wet Age-Related Macular Degeneration (AMD) Drugs Market- Global Opportunity Analysis and Industry Forecast, 2020-2027
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5,370$4,833 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $0.00
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. Subscription @ $559 T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.